Peptide May Benefit Idiopathic Pulmonary Fibrosis Patients | RT
Two posters presented at ATS 2025 offered data on Rein Therapeutics’ novel peptide LTI-03’s potential clinical value for idiopathic pulmonary fibrosis patients. RT’s Three Key Takeaways: Dual Mechanism of Acti…
Read guide →